Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer
- 1 April 2023
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (10), 1952-1953
- https://doi.org/10.1200/jco.22.02596
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III TrialJournal of Clinical Oncology, 2023
- Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical StudyJAMA Oncology, 2018
- Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard RatioJAMA Oncology, 2017
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival AnalysisJournal of Clinical Oncology, 2014